Dr. Lederer is a pulmonologist and Medical Director at Regeneron Pharmaceuticals where he leads clinical trials in advanced lung diseases. Prior to joining Regeneron, he was an Associate Professor of Medicine and Epidemiology at Columbia University Medical Center in New York, where he led an NHLBI-funded clinical and epidemiological research program. His research included the development of a novel method of measuring early lung inflammation and extracellular matrix remodeling detected years before the onset of pulmonary fibrosis using quantitative CT imaging. He also led the NHLBI-funded Lung Transplant Body Composition study which identified obesity, sarcopenia, and frailty as clinically relevant body composition phenotypes in adults with advanced lung disease. Dr. Lederer was previously the Editor-in-Chief of the Annals of the American Thoracic Society. After serving as a Senior Medical Advisor for the Pulmonary Fibrosis Foundation for 5 years, Dr. Lederer is now a member of the Foundation’s Medical and Scientific Advisory Board.
